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Docetaxel (DTX) has been known to have excellent therapeutic effects for a wide 
spectrum of cancers such as breast cancer, ovarian cancer and head and neck cancer. 
Due to its low solubility, the clinical application of docetaxel (Taxotere®) is 
formulated with an adjuvant consisting of non-ionic surfactant polysorbate 80 and 
ethanol which has been found to cause harmful side effects. This problem of solubility 
can be solved by conjugating Docetaxel with D-α-Tocopheryl Polyethylene Glycol 
Succinate (TPGS) which is a water soluble derivative of natural vitamin E. Co 
administration of vitamin E TPGS has been found to enhance cytotoxicity, inhibit 
multi drug resistance and increase oral bioavailability of anticancer drugs, making it a 
suitable component for the prodrug. Therefore, the focus of this project is to develop a 
prodrug consisting of TPGS and DTX. 
 
TPGS-DTX conjugate was prepared by attachment of TPGS to DTX through an ester 
linkage. This was done by a two step synthesis which consists of activation of TPGS to 
obtain a carboxyl group and further reaction of the carboxyl group with one of the 
hydroxyl groups of DTX. The conjugate was characterized by ˡH NMR to ensure that 
conjugation has taken place. The molecular weight of the conjugate was found using 
GPC which also further confirmed the conjugation of TPGS to the drug. 
 
In vitro release studies of TPGS-DTX were investigated by a dialysis method in PBS 
at pH 3.0, 5.0 and 7.4 respectively at 37
o
C. As DTX was probably released from the 
TPGS-DTX conjugate by hydrolysis of the ester linkage, faster drug release was 
observed at lower pH. This effect is desirable as drug release inside cancer cells could 
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be sped up when the conjugate is exposed to the acidic pH of the lysosome. In vitro 
cytotoxicity of TPGS-DTX conjugate was evaluated by MTT assay against MCF-7 
breast cancer cell lines. From the IC50 values, the conjugate was found to be 30.9% and 
98.6% more effective when cultured with MCF-7 cells for 48 and 72 h respectively. In 
addition, in vivo pharmacokinetics studies showed that the half-life (t1/2 ) of  TPGS-
DTX was found to be  23-fold longer than that for Taxotere® and the total AUC (area-
under-curve) for TPGS-DTX was 8.6-fold larger than that of Taxotere®, indicating 
that the prodrug formulation has higher therapeutic effect than Taxotere®.  
 
To further enhance the TPGS-DTX conjugate, another conjugate, TPGS-HER-DTX 
was synthesized to incorporate the added advantage of Herceptin (HER) as the 
targeting moiety. As HER2 is over-expressed in breast cancer cells, Herceptin has been 
approved by US FDA as a therapeutic agent for HER2 over-expressing breast cancer. 
The TPGS-HER-DTX conjugate was prepared by a three step synthesis which 
involved the activation of DTX and TPGS individually to obtain carboxyl groups and 
the formation of amide linkages between the activated DTX and TPGS to HER with 
the help of N-hydroxysuccinimide (NHS). The successful conjugation of TPGS-HER-
DTX has been confirmed by MALDI-TOF and GPC studies, showing potential of a 
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CHAPTER 1 INTRODUCTION 
 
1.1. Background 
Chemotherapy, defined as the use of chemicals for treatment of any disease, provides 
hope for patients afflicted with cancer. (Devita and Chu, 2008) However, inherent 
factors like low solubility, toxicity, drug resistance and the inability to cross the 
microcirculatory barrier seriously hinder the potential benefits such an approach can 
provide.(Ramachandran and Melnick, 1999)  
Over the years, due to the need to produce drugs with better efficacy, 
chemotherapeutic engineering has been an emerging discipline in the biomedical field. 
Chemotherapeutic engineering aims to develop innovative drug delivery systems 
which are being designed to guide drugs more precisely to tumour cells and away from 
sites if toxicity and/or maintain drugs at a therapeutic concentration over long periods 
of time.(Feng and Chien, 2003) Prodrug is an example of these drug delivery systems 
that have been formulated. By forming a drug that remains inactive during its delivery 
to the site of action and is activated by the specific conditions in the targeted site, the 
problem of toxicity to normal cells is expected to be greatly reduced. Normally, a 
prodrug consists of a drug connected to a polymer to from a conjugate. (Rautio et al., 
2008; Li and Wallace, 2008) In most cases, the presence of the polymer enhances the 
solubility of the hydrophobic drug and improves its pharmacokinetic  profile (Meerum 
terwogt et al., 2001; Vasey et al., 1999) while increasing plasma half-life and volume 
of distribution. It also reduces clearance by the kidneys or liver and protects the drug 
against degradation (Yurkovetskiy and Fram, 2009). In addition, a targeting moiety or 
a solubilizer may also be introduced into the conjugate to boost its therapeutic index. 
(Sanchis et al., 2010) Currently, more than 14 polymer–drug conjugates have already 
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reached clinical trials, making polymer-drug conjugates a much sought after drug 
delivery system. (Duncan, 2006; Rautio et al., 2008) Polymers such  as                            
N-(2-hydroxypropyl)methacrylamide (HPMA)  copolymers,  poly(ethylene  glycol)  
and poly(L-glutamic  acid)  (PGA)  have  been  used  often  as  the  carriers  for  
anticancer  drugs  such  as doxorubicin,  paclitaxel,  camphothecin  and  gemcitabine. 
(Pasut and Veronese, 2007; Chytil et al., 2006; Greenwald et al., 2003) Several  
polymeric  conjugates,  for  example,  PEG conjugation   of   paclitaxel,   
camptothecin,   methotrexate,   and Docetaxel have been developed earlier (Maeda et 
al., 1992; Li et al., 1996; Riebeseel et al., 2002; Veronese et al., 2005) 
1
  
Docetaxel (DTX) has been known to have excellent therapeutic effects for a wide 
spectrum of cancers such as breast cancer, ovarian cancer and head and neck cancer. 
However it has low solubility and the clinical dosage form of docetaxel (Taxotere®) is 
formulated in the adjuvant consisting of non-ionic surfactant polysorbate 80 and 
ethanol which has been found to cause harmful side effects.
2
 This problem of solubility 
can be solved by conjugating Docetaxel with TPGS. TPGS is a water soluble 
derivative of natural vitamin E. Its bulky structure and large surface area makes it an 
excellent emulsifier. It has been found that co administration of vitamin E TPGS could 
enhance cytotoxicity, inhibit multi drug resistance and increase oral bioavailability of 
anticancer drugs, thus making it a suitable component for the prodrug. Previously, 
TPGS has been used to conjugate with Doxorubicin (Cao and Feng, 2008) and further 
conjugated with folic acid (Anbharasi et al., 2010). Desirable in vitro and in vivo 
results have been achieved indicating the feasibility of drug conjugation with TPGS. 
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To have the ability to exclusively target cancer cells, Herceptin is introduced as the 
targeting moiety in the later part of the thesis. As HER2 is over-expressed in breast 
cancer cells, Herceptin is a potential receptor to target HER2-overexpressing breast 
cancer cells. It can specifically bind to the membrane region of HER2 /neu with a high 
affinity. In addition, Herceptin has been approved by US FDA as a therapeutic agent 
for HER2 over-expressing breast cancer. (Nahta and Esteva, 2006; Ranson and 




The objectives of this research are to develop a novel polymeric prodrug, TPGS-DTX, 
with a hope to enhance the therapeutic potential and reduce the systemic side effects of 
the drug. The polymer-drug conjugation was confirmed by ¹H NMR and GPC. In vitro 
drug release studies were carried out to see the effect pH on drug release from the 
conjugate.  In  vitro cytotoxicity  studies of TPGS-DTX were investigated by using 
MCF-7 breast cancer cells in close comparison with the pristine drug. In addition, 
pharmacokinetics of TPGS-DTX was investigated in SpD rats in comparison with 
Taxotere®. 
 
To have an added targeting advantage, another conjugate, TPGS-HER-DTX was also 
synthesised to see the feasibility of conjugating both a polymer and a targeting moiety 






1.3.   Thesis Organization 
 
In this thesis, we focus on the polymer drug conjugation of TPGS and Docetaxel and 
introduce the conjugation of TPGS with Docetaxel and Herceptin. The first chapter of 
this thesis is to give a general background and an introduction to the concepts of 
prodrug conjugation. Next, chapter 2 gives a literature review on cancer and the 
current progress in the related fields of drug delivery.  Chapter 3 introduces the TPGS-
DTX conjugation, with synthesis methods and characterization studies. In vitro studies 
of TPGS-DTX, including in vitro drug release and in vitro cytotoxicity studies, are 
discussed in Chapter 4. In vivo studies of the conjugate can be found in Chapter 5. 
Chapter 6 introduces the synthesis and characterization of the TPGS-HER-DTX 












CHAPTER 2 LITERATURE REVIEW 
2.1  Cancer 
2.1.1 What is Cancer 
Cancer is a term used for diseases in which abnormal cells divide without control and 
are able to invade other tissues. Cancer cells can spread to other parts of the body 
through the blood and lymph systems and cause death if not controlled. 
3
  Due to the 
increasing and aging population, the number of global cancer deaths is projected to 
increase 45% from 2007 to 2030 (from 7.9 million to 11.5 million deaths) despite 
having taken into account expected slight declines in death rates for some cancers in 
high resource countries. New cases of cancer in the same period are estimated to jump 
from 11.3 million in 2007 to 15.5 million in 2030, making cancer the second largest 
cause of death after cardiovascular disease. With the biggest killer being lung cancer, 
prostate, breast and colon cancer are more common in developed countries while liver, 




        
Figure 2.1: Diagram showing a) how normal cells make up the tissue in our body, and 

















2.1.2 Causes of Cancer 
As cancer arises due to abnormalities in cell growth, malfunction of genes that control 
cell division is apparent in all cancers. With only about 5% of all cancers being 
strongly hereditary, most cancers do not result from inherited genes but from damage 
to genes occurring during one’s lifetime. An example of this phenomenon is the 
genetic predisposition of the BRCA1 and BRCA2 breast cancer genes. Women who 
carry one of these mutated genes have a higher chance of developing breast cancer 
than women who do not but most women with breast cancer do not have a mutated 
BRCA1 or BRCA 2 gene. Less than 5% of all breast cancer is due to these genes. 
Therefore, although women with one of these genes are individually have a higher risk 




Even though it is possible for just anyone to develop cancer, the risk of being 
diagnosed with cancer increases with age with most cases occurring in adults who are 
middle age or older. It has been found that 78% of all cancers are diagnosed in persons 
55 years and older.
7
 This is due to the fact that the genes within a cell have to go 
through a number of changes before it turns into a cancer cell. These changes can 
occur randomly during cell division or they can be passed down from a cell which has 
suffered damage by carcinogens. The longer we live, the more chances there are for 
these genetic mistakes to happen in our cells. Other than inherited genes and aging, 
genetic damage may result from internal factors, such as hormones, or poor immune 
system, or external factors, such as tobacco use, diet and lack of exercise or exposure 
to chemicals, radiation and sunlight. 








Tobacco use is the most preventable cause of cancer. Smoking is responsible for 
almost 9 out of 10 lung cancer deaths. Lung cancer is the leading cause of cancer death 
in both men and women, and is one of the hardest cancers to treat. Other than the lung 
cancer, smokers are also more likely to develop cancer of the larynx, mouth, 
oesophagus, bladder, kidney, throat, stomach, pancreas, or cervix than non-smokers. 
8
  
In addition, long term exposure to environmental smoke at home or at work increases 
the risk of lung cancer. It also increases the risk of cancer of the larynx and pharyngeal 
cancer. Exposure to environmental tobacco smoke in childhood may cause bladder 
cancer later in life. 
Diet and lack of exercise 
An individual’s diet is also an important lifestyle factor related to cancer risk. Studies 
show that consuming large quantities of red meat, preserved meats, salt-preserved 
meats, and high salt intake probably increases the risk of stomach and colorectal 
cancers. Research has shown that a diet high in fruits and vegetables may decrease the 
risks of these cancers. There are also links between obesity and the risks of breast 
cancer in older women, endometrial cancer, and cancers of the kidney, colon, and 
oesophagus.  
People with high alcohol consumption also have an increased risk of cancers of the 
mouth, throat, liver, voice box, and oesophagus. There is also some evidence for an 






increased risk of breast cancer. Drinkers who also smoke may have an even higher risk 
of some oral and throat cancers.
9
 
Not being physically active increases the risk of colorectal and breast cancers. 
Together, obesity and physical inactivity are linked to about 30% of the cases of colon, 
endometrial, kidney, and oesophageal cancers, as well as 30% of breast cancers in 
older women.  
 
Exposure to sunlight, chemicals and radiation 
Skin cancer is the most common of all cancer which accounts for nearly half of all 
cancers in the United States. Non-melanoma skin cancer is more or less linked to 
constant sun exposure over the years while melanoma, the most serious form of 
cancer, is linked to exposing untanned skin to the sun in relatively short bursts. An 
example would be tanning on the beach during a short trip to a hot country. This is 
thought to be particularly dangerous in babies, children and young adolescents. Risk of 
getting melanoma can be lowered by avoiding intense sunlight for long periods of time 
and by practicing sun safety such as putting on sun-screen.  
Exposure to ionizing radiation can cause cell damage that leads to cancer. This kind of 
radiation comes from rays that enter the Earth's atmosphere from outer space, 
radioactive fallout, radon gas, x-rays, and other sources. Radioactive fallout can result 
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from accidents at nuclear power plants or from the production, testing, or use of atomic 
weapons. People exposed to fallout may have an increased risk of cancer, especially 
leukaemia and cancers of the thyroid, breast, lung, and stomach.  
Radon is a radioactive gas that is odourless and non-visible. It forms in soil and rocks 
and thus people who work in mines may have higher exposure to radon and in turn are 
at increased risk of lung cancer.
11
  
Ten or more years often pass between exposure to external factors and detectable 
cancer. These causal factors, both internal and external, may act together or in 










 http://www.cancer.gov/cancertopics/ wyntk/cancer/page4 
12
 http://www.cancer.org/research/cancer factsfigures/cancerfactsfigures/cancer-facts-and-figures-2010 
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2.1.3 Treatments of Cancer 
Treatments available for cancer include surgery, radiotherapy, chemotherapy, hormone 
therapy and immunotherapy. A combination of the treatments is usually required to 
produce most effective results. 
Surgery involves the physical removal of tumours. Although surgical removal of 
cancerous tumours and the surrounding affected tissue is often effective and 
considered as the primary procedure for tumours large enough to manipulate, it is 
difficult for surgery to be thorough. Furthermore, surgery is not appropriate for 
undetectable cancer, metastatic cancer or cancer not confined in a solid tumour. 
Excision of the tumour could also lead to changing the growth rate of the remaining 
cancer cells by triggering a faster metastatic process. This leads to combination of 
chemotherapy and other treatments being the primary and standard treatments of 
cancers. (Feng and Chien, 2003) 
Radiotherapy 
Radiation  therapy  is  the  use  of  ionizing  radiation  to  kill  cancer  cells  and  shrink 
tumours.  It  can  be  administered  externally  or  internally.  The  effects  of  radiation  
therapy  are localized and confined to the region being treated. Radiation therapy 
injures or destroys cells in the area being treated by damaging their genetic material, 
making it impossible for these cells to continue  to  grow  and  divide.  Although  
radiation  damages  both  cancer  cells  and  normal  cells, most  normal  cells  can  
recover  from  the  effects  of  radiation  and  function  properly.  The  goal  of 
radiation therapy is to damage as  many cancer cells as possible, while limiting harm to 
nearby healthy tissue. Radiation therapy may be used to treat almost every type of 
11 
 
solid tumour, including cancers of the brain, breast, cervix, larynx, lung, pancreas, 
prostate, skin, stomach, uterus, or soft tissue  sarcomas.  Radiation  is  also  used  to  
treat  leukaemia  and  lymphoma.   
Hormone therapy 
Hormone therapy uses sex hormones, or hormone-like drugs, that alter the action or 
production of female or male hormones. They are used to slow the growth of breast, 
prostate, and endometrial (uterine) cancers, which normally grow in response to 
natural hormones in the body. These cancer treatment hormones do not work in the 
same ways as standard chemotherapy drugs, but rather by preventing the cancer cell 
from using the hormone it needs to grow, or by preventing the body from making the 
hormones. 
Immunotherapy 
Some drugs are given to people with cancer to stimulate their natural immune systems 
to be able to recognize and attack cancer cells more effectively. These drugs offer a 
unique method of treatment, and are often considered to be separate from 
chemotherapy. There are different types of immunotherapy. Active immunotherapies 
stimulate the body's own immune system to fight the disease. Passive immunotherapies 
do not rely on the body to attack the disease; instead, they use immune system 






2.2 Cancer Chemotherapy and Chemotherapeutic Engineering 
2.2.1 Chemotherapy 
Chemotherapy is defined as the use of chemicals for the treatment of any disease. 
(Devita and Chu, 2008) For cancer, chemotherapy carries a high risk due to drug 
toxicity as the chemotherapeutical agents used to kill or control cancer cells may harm 
the normal cells too. Patients will have to tolerate severe side effects and sacrifice their 
quality of life. The effectiveness of chemotherapy depends on many factors including 








2.2.2 Types of Anticancer drugs 
Chemotherapy drugs can be divided into several groups based on factors such as how 
they work, their chemical structure, and their relationship to another drug. Some drugs 
may belong to more than one group as they act in more than one way.  
Alkylating agents  
Alkylating agents directly damage DNA to prevent the cancer cell from reproducing. 
These agents are not phase-specific and are used to treat many different cancers, 
including acute and chronic leukaemia, lymphoma, Hodgkin disease, multiple 
myeloma, sarcoma, as well as cancers of the lung, breast, and ovary. As these drugs 
work by damaging DNA, they can cause long-term damage to the bone marrow. In a 
few rare cases, this can eventually lead to acute leukaemia. The risk of leukaemia from 
alkylating agents is dose-dependent, with the risk being highest 5 to 10 years after 
treatment. Alkylating agents include Nitrogen mustards, Nitrosoureas, Alkyl 
sulfonates, Triazines, Ethylenimines Platinum drugs (cisplatin, carboplatin, and 
oxalaplatin) are sometimes grouped with alkylating agents because they kill cells in a 
similar way. These drugs are less likely than the alkylating agents to cause leukaemia. 
Antimetabolites  
Antimetabolites interfere the growth of DNA and RNA by substituting for the normal 
building blocks of RNA and DNA. These agents damage cells during the S phase and 
are commonly used to treat leukaemia, tumours of the breast, ovary, and the intestinal 




Anthracyclines are anti-tumour antibiotics that interfere with enzymes involved in 
DNA replication. As these agents work in all phases of the cell cycle, they are widely 
used for a variety of cancers. A major consideration when giving these drugs is that 
they can permanently damage the heart if given in high doses. For this reason, lifetime 
dose limits are often placed on these drugs. Examples of anthracyclines include 
daunorubicin, doxorubicin (Adriamycin®), epirubicin, and idarubicin.  
Other anti-tumour antibiotics include the drugs actinomycin-D, bleomycin, and 
mitomycin-C. Mitoxantrone is an anti-tumour antibiotic that is similar to doxorubicin 
in many ways, including the potential for damaging the heart. This drug also acts as a 
topoisomerase II inhibitor and can lead to treatment-related leukaemia. Mitoxantrone 
is used to treat prostate cancer, breast cancer, lymphoma, and leukaemia. 
Topoisomerase inhibitors 
These drugs interfere with enzymes called topoisomerases, which help separate the 
strands of DNA so they can be copied. They are used to treat certain leukaemia, as 
well as lung, ovarian, gastrointestinal, and other cancers. Examples of topoisomerase I 
inhibitors include topotecan and irinotecan (CPT-11). Examples of topoisomerase II 
inhibitors include etoposide (VP-16) and teniposide. Mitoxantrone also inhibits 
topoisomerase II. 
Treatment with topoisomerase II inhibitors increases the risk of a second cancer -- 
acute myelogenous leukaemia (AML). Secondary leukaemia can be seen as early as 2 
to 3 years after the drug is given. 
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Mitotic inhibitors  
Mitotic inhibitors are often plant alkaloids and other compounds derived from natural 
products. They can stop mitosis or inhibit enzymes from making proteins needed for 
cell reproduction. These drugs work during the M phase of the cell cycle, but have the 
ability to damage cells in all phases. They are used to treat many different types of 
cancer including breast, lung, myelomas, lymphomas, and leukaemia. These drugs are 
known for their potential to cause peripheral nerve damage, which can be a dose-
limiting side effect. Examples of mitotic inhibitors include Taxanes: paclitaxel 
(Taxol®) and docetaxel (Taxotere®).  
Corticosteroids 
Steroids are natural hormones and hormone-like drugs that are useful in treating some 
types of cancer (lymphoma, leukaemia, and multiple myeloma), as well as other 
illnesses. When these drugs are used to kill cancer cells or slow their growth, they are 
considered chemotherapy drugs. Corticosteroids are also commonly used as anti-
emetics to help prevent nausea and vomiting caused by chemotherapy. They are used 
before chemotherapy to help prevent severe allergic reactions (hypersensitivity 
reactions), too. When a corticosteroid is used to prevent vomiting or allergic reactions, 
it is not considered chemotherapy. Examples include prednisone, methylprednisolone 
(Solumedrol®) and dexamethasone (Decadron®).  
Targeted therapies 
As researchers have learned more about the inner workings of cancer cells, they have 
begun to create new drugs that attack cancer cells more specifically than traditional 
chemotherapy drugs. Most attack cells with mutant versions of certain genes, or cells 
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that express too many copies of a particular gene. These drugs can be used as part of 
primary treatment or after treatment to maintain remission or decrease the chance of 
recurrence. 
Differentiating agents 
These drugs act on the cancer cells to make them mature into normal cells. Examples 
include the retinoids, tretinoin (ATRA or Atralin®) and bexarotene (Targretin®), as 
well as arsenic trioxide (Arsenox®).
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2.2.3 Limitations of Chemotherapy 
Problems in chemotherapy arise due to toxicity. This toxicity could be attributed from 
the drug itself or its dosage forms or the levels in which the drug is administered. Most 
anticancer drugs are highly hydrophobic and have to be used with adjuvants for 
clinical administration. Some of these adjuvants are life threatening.(Feng and Chien, 
2003) An example is Docetaxel (DTX) which has been approved for treatment of 
locally advanced and metastatic breast cancer, non-small cell lung cancer, androgen-
independent prostate cancer, and advanced gastric cancer (Kintzel et al., 2006). 
Taxotere®, the commercially available formulation of DTX consists of the drug 
solubilised in polysorbate 80 at 40 mg/mL.
14
 Prior to use, Taxotere® must be diluted, 
in order to prevent drug precipitation in plasma, reducing the concentration of DTX to 
0.74 mg/mL(Liu et al., 2008)
 
Consequently, in order to achieve a high enough clinical 
dose,. use of this formulation requires a 2–3 h infusion. In addition, the excipient 
polysorbate 80 has been associated with hypersensitivity reactions and peripheral 
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neurotoxicity, which are the main side effects of Taxotere® (Vanhoefer et al., 1997; 
Van zuylen et al., 2001; Kaye, 1995) 
 
Drug resistance is also another factor that affects the effectiveness of chemotherapy. 
Cancer cells tend to develop resistance to the drugs when used long term. As more 
than one drug is normally used in clinical oncology, resistance can develop against 
multiple anticancer drugs with certain special types of molecular structure, i.e., 
multidrug resistance (MDR). Decreased drug accumulation in MDR cells has been 
found to be associated with an over-expression of P-glycoprotein (P-gp), which is a 
glycoprotein in the cell membrane. P-gp pumps the drugs out of cells by a mechanism 
that requires ATP. A variety of tissues have been found to express P-gp in an inducible 
form, e.g., in kidney, liver, small intestine, colon, uterine epithelium, and adrenal 
gland. The normal function of P-gp has not been firmly established, but it is well 
known that P-gp can cause the removal of toxic substances from the cells.(Feng and 
Chien, 2003; Gatmaitan and Arias, 1993) 
 
Another problem in chemotherapy is the microcirculatory barrier, which blood borne 
therapeutic agents must cross to reach the cancer cells. Without reaching the cancer 









2.2.4 Chemotherapeutic Engineering 
The limitations of chemotherapy has led to the need for chemotherapeutic engineering 
which can be defined as the application and development of engineering principles and 
devices for chemotherapy of cancer and other diseases to achieve the best efficacy with 
the least side effects.(Feng and Chien, 2003) Chemotherapeutic engineering aims to 
develop innovative drug-delivery systems which are designed to guide drugs more 
precisely to tumour cells and away from sites of toxicity, and/or to maintain drugs at a 
therapeutic concentration over long periods of time.  
 
2.3 Drug Delivery Systems for Cancer Chemotherapy 
2.3.1 Liposomes 
Liposomes are spherical  vesicles  composed of amphiphilic phospholipids and 
cholesterol, which self-associate into  bilayers  to  encapsulate  an  aqueous  
interior.(Torchilin and Weissing, 2003) A closed bilayer sphere is formed by the 
amphiphilic phospholipid molecules in an attempt to shield their hydrophobic groups 
from the  aqueous  environment,  while  maintaining  contact with  the  aqueous  phase  
via  the  hydrophilic  head  group. 
 
Drugs with widely varying lipophilicities can be encapsulated  in  liposomes,  in  the  
phospholipid  bilayer,  in  the entrapped  aqueous  volume,  or  at  the  bilayer  
interface. Although liposomes vary greatly in size, most are 400 nm or less. (Muthu 
and Singh, 2009) Liposome surfaces can be modified by attaching PEG units to the 
bilayer to enhance their circulation time in the bloodstream. Doxil®, a long-acting 
PEGylated liposomal formulation of doxorubicin, is known for its significant 
improvements over doxorubicin. Daunorubicin (Daunoxome ® ) is being marketed 
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currently in liposome delivery systems, whereas vincristine (Onco TCS TM ) awaits 
FDA approval (Lasic, 1998; Piccaluga et al., 2002; Waterhouse et al., 2005).  
 
Despite this success, there have been major drawbacks to the use of liposomes for 
targeted drug delivery. Some of the major problems include poor control over the 
release of the drug from the liposomes, poor stability, poor batch-to-batch 
reproducibility, difficulties in sterilization and low drug loading.(Torchilin, 2005; 
Bawarski et al., 2008) 
 
Figure 2.4: Diagram of Liposomal-based system with targeting or PEG groups either 
preconjugated with a lipid then formed into a vesicle or post inserted into the liposome 
(Fahmy et al., 2005) 
 
2.3.2 Polymer Micelles 
Micelles are nanosized, spherical colloidal particles with a  hydrophobic  interior  
(core)  and  a  hydrophilic  exterior (shell).  Their  main  utility  is  in  the  preparation  
of pharmaceutical  formulations, notably agents which are regularly soluble in water. 
(Torchilin, 2007) Drugs may be  entrapped  within  the  hydrophobic  core  or  linked 
covalently  to  the  surface  of  micelles.  With individual particle sizes less than 50 nm 
in diameter, micelles provide obvious benefits over liposomes such as prolonged 
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circulation in the blood. They can be used to gradually release drugs and facilitate in 
vivo imaging. To support prolonged systemic  circulation,  shells  of  polymeric  
micelles  can be designed  to  be  thermodynamically  stable  and  biocompatible. 
(Gaucher et al., 2005; Adams et al., 2003) As many  existing  solvents  for  poorly  
water- soluble  pharmaceuticals,  like  Cremophor  EL  (BASF)  or ethanol, can be 
toxic, polymeric  micelles  provide  a safer  alternative  for  parenteral  administration  
of  poorly water-soluble  drugs like amphotericin B, propofol and paclitaxel. For the 
formation of micelles, amphiphilic  molecules  must  have  both  hydrophobic  and 
hydrophilic segments, where the hydrophilic fragments form the micelle shell and the 
hydrophobic fragment forms the core. Thus, in aqueous media, the core of the micelles 
can solubilise water-insoluble  drugs;  the  surface  can  adsorb polar molecules, 
whereas drugs with intermediate polarity can be distributed along with the surfactant 
molecules in intermediate positions. The mechanism of solubilisation and utilization  
of  micelles  has  been  extensively  studied  by various researchers. A schematic 
diagram of the formation of micelles from an amphiphilic molecule and the loading of 
hydrophobic drugs are shown in Figure 2.5. Similar to liposomes, polymeric micelles 
can be modified using  piloting  ligand  molecules  for  targeted  delivery  to specific 
cells (i.e., cancer cells). pH-sensitive drug-binding linkers can be added for controlled 
drug release and multifunctional polymeric  micelles can  be  designed  to  facilitate  





Figure 2.5: Micelle formation A, Formation of micelles in aqueous media B, 
Formation of micelles in aqueous media incorporating drugs. (Bawarski et al., 2008) 
 
 
Figure 2.6: Polymeric micelles using targeting ligand/molecules for active targeting 
(Muthu and Singh, 2009) 
 
2.3.3 Dendrimers 
Dendrimers are a unique class of polymeric macromolecules synthesized via divergent 
or convergent synthesis by a series of controlled polymerization reactions. 
Characteristically, the structure of these polymers is repeated branching around the 
central core that results in a nearly-perfect three-dimensional  geometrical  pattern.  At  
higher  generations (greater  than  five)  dendrimers  resemble  spheres  with countless 
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cavities within their branches to hold therapeutic and diagnostic agents. Dendrimers 
used in targeted drug delivery are usually 10 to 100 nm.(Bawarski et al., 2008) 
 
Figure 2.7: A dendrimer (Muthu and Singh, 2009) 
 
A polyamidoamine dendrimer that can be synthesized by the repetitive addition of 
branching units to an amine core (ammonia or ethylenediamine) is an example of such 
an application. Polyamidoamine cores can function as drug reservoirs and have been 
studied  as  vehicles  for  delivery  of  drugs, genetic material, and imaging probes. 
Other pharmaceutical applications of dendrimers include nonsteroidal anti-
inflammatory  formulations,  antimicrobial  and  antiviral  drugs, anticancer  agents, 
pro-drugs,  and  screening  agents  for high-throughput drug discovery. (Cheng et al., 
2008; Cheng et al., 2007; Kojima et al., 2000) 
 
As dendrimers may be toxic due to their ability to disrupt cell membranes as a result 
of a positive charge on their surface, there  is  concern  about  the  interaction  between  
dendrimers  and  the  cell membrane.  Relying  on  the  active  functional  end  groups  
on  the  surface  of  dendrimers, positively-charged  surface  has  potential  disruptive  
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effect  of  hole  formation  to  the phospholipid  membrane  of  cells  compared  to  
negatively-charged  or  neutral  dendrimers. Besides that, size (generations) of the 
dendrimers is also a key factor in determining the biocompatibility  of  the  dendritic  
devices  (Wolinsky  and  Grinstaff,  2008).  Large  and positively-charged amine-
coated melamine dendrimers, for instance, are found to induce in  vivo  hemolytic  
toxicity  compared  to  non-cytotoxic  neutral  PEGylated  melamine dendrimers,  thus  
raising  the  questions  on  suitability  of  dendrimers  as  delivery  devices (Chen  et  
al.,  2004).  Therefore,  the  mechanistic  and  chemical  understandings  of  the 
dendrimer’s architecture have to be well-studied when designing more biocompatible 



















2.4.1 Concept of Prodrugs 
A prodrug is defined as a chemical derivative of an active parent drug which has 
modified physicochemical properties such as aqueous solubility, while keeping the 
inherent pharmacological properties of the drug intact. Prodrugs are kept inactive by 
linking with a promoiety/promoieties which gives the original drug added advantages. 
Prodrug reconversion (i.e. its conversion into its active form) occurs in the body inside 
a specific organ, tissue or cell. In most cases, normal metabolic processes such as the 
cleavage of a bond between a promoiety and a drug by specific cellular enzymes are 
utilized to achieve prodrug reconversion. (Khandare and Minko, 2006) 
The idea of covalently attaching chemotherapeutic agents to a water-soluble polymer 
was first proposed by Ringsdorf in the mid-1970s. In this model, it was envisioned that 
not only could  the  pharmacokinetics  of  the  drug  attached  to  the polymeric carrier 
be modulated but also that active targeting could be achieved if a homing moiety was 
introduced to the same  polymeric  carrier.  Since then, polymer-drug conjugates have 
become a fast-growing field, with nearly a dozen polymeric conjugates advancing to 
the clinical trial stage. (Li and Wallace, 2008) 
 
Figure 2.8: Ringsdorf model of polymer-drug conjugate consisted of five main 
elements: polymeric backbone, drug, spacer, targeting group, solubilising moiety. (Qiu 
and Bae, 2006) 
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In general, a prodrug consists of a drug, solubilising moiety and/or a targeting group 
connected directly or through a suitable linker to form a conjugate. The conjugate 
should be systemically non-toxic, meaning that the linker must be stable in circulation. 
Upon internalization into the cancer cell the conjugate should be readily cleaved to 
regenerate the active cytotoxic agent. (Jaracz et al., 2005) 
 
Bearing in mind that prodrugs might alter the tissue distribution, efficacy and the 
toxicity of the parent drug, several important factors should be taken to consideration 
when designing a prodrug structure.(Rautio et al., 2008) 
 
The main factors include: 
1)  Parent drug structure: 
The functional groups available on the parent drug will determine the method of 
conjugation between the promoiety and the drug and the method by which the 
conjugate is cleaved. Some of the most common functional groups that are amenable 
to prodrug design include carboxylic, hydroxyl, amine, phosphate/phosphonate and 
carbonyl groups. Prodrugs typically produced via the modification of these groups 






Figure 2.9: Common functional groups on parent drugs that are amenable to prodrug 
design (shown in green). (Rautio et al., 2008) 
 
 
2) Choice of Promoiety/carrier 
An ideal carrier should be without intrinsic toxicity. It should be non-immunogenic 
and non-antigenic and should not accumulate in the body. In addition, it should 
possess a suitable number of functional groups for drug attachment and adequate 
loading capacity. It should be stable to chemical manipulation and autoclaving. It 
should be easy to characterize and should mask the attached drug’s activity until 
release of active agent at the desired site of action. The choice of promoiety used 




3) Parent and prodrug properties: 
The absorption, distribution, metabolism, excretion (ADME) and pharmacokinetic 
properties need to be comprehensively understood. Parent drug and prodrug properties 
should be extensively considered to provide the best drug design.(Rautio et al., 2008) 
 
4) Degradation by-products of the Prodrug: 
Degradation can affect chemical and physical stability and lead to the formation of 
new degradation products. Degradation products should have low circulation time 




2.4.2 Mechanism of prodrugs 
 
Figure 2.10: Current Understanding of the mechanism of action of polymer-drug 
conjugate 
 
Polymer–drug conjugates administered intravenously can be designed to remain in the 
circulation as their clearance rate depends on conjugate molecular weight, which 
governs the rate of renal elimination. Drug that is covalently bound by a linker that is 
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stable in the circulation is largely prevented from accessing normal tissues (including 
sites of potential toxicity), and biodistribution is initially limited to the blood pool. The 
blood concentration of drug conjugate drives tumour targeting due to the increased 
permeability of angiogenic tumour vasculature (compared with normal vessels), 
providing the opportunity for passive targeting due to the enhanced permeability and 
retention effect (EPR effect).  Through the incorporation of cell-specific recognition 
ligands it is possible to bring about the added benefit of receptor-mediated targeting of 
tumour cells. (Duncan, 2006) 
2.4.2.1 Passive targeting  
Passive targeting approaches include:  (1) the enhanced permeability and retention 
(EPR) effect, (2) the use of special conditions in tumour or tumour-bearing organ and 
(3) topical delivery directly to the tumour. The EPR effect was first described by 
Matsumura  and  Maeda  in  1986.  The  EPR  effect  is  the  result  of  the  increased 
permeability  of  the  tumour  vascular  endothelium  to  circulating  macromolecules 
together with limited lymphatic drainage from the tumour interstitium. Low molecular 
drugs  coupled  with  high  molecular  weight  carriers  are  inefficiently  removed  by  
 lymphatic  drainage  and  therefore  accumulate  in  tumours.  Theoretically,  any  high  
molecular water-soluble drug carrier should show such an effect too, including water-
soluble polymers, liposomes, etc. The existence of the EPR effect was experimentally 
confirmed  for  the  many  types  of  macromolecular  anticancer  drug  delivery  
systems. (David, 2004) It  is  now  generally  accepted  and  considered  as  a  major  
rational  for  using polymeric prodrugs. Passive targeting increases the concentration 
of the conjugate in the  tumour  environment  and  therefore  ‘passively’  forces  the  
polymeric  drug  to  enter the  cells  by  means  of  the  concentration  gradient  
between  the  intracellular  and extracellular spaces.  
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2.4.2.2 Active targeting   
Active  targeting  could  be  achieved by  adding  a  targeting  component  to  a  drug  
delivery  system  that  would  result  in preferential  accumulation  of  the  drug  in  a  
targeted  organ,  tissue,  cells,  intracellular organelles  or  certain  molecules  in  
specific  cells,  This approach makes use of the interactions between a ligand and a 
receptor or between a specific biological pair for example an antibody and an antigen. 
Usually,  a  targeting  moiety  in  a  polymeric  drug  delivery  system  is  directed  at  
the specific  receptor  or  antigen  over-expressed  in  the  plasma  membrane  or  
intracellular membrane  of  the  targeted  cells.  Monoclonal  antibodies  used  as  
targeting  group selectively seek out the tumour cells by binding to such tumour 
specific antigens. As a result, the drug conjugate should bind very specifically to these 
tumour cells.(Ram and Tyle, 1987) The interaction  of  the  target  moiety  with  their  
receptor  initiates  receptor  –mediated endocytosis. It is an active process that requires 
a much lower concentration gradient across the plasma membrane when compared to 
simple endocytosis. This process is schematically shown in Figure 2.11.  
 
Figure 2.11: Main stages of receptor-mediated endocytosis  
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As  the  targeted  carrier  interacts  with  the  corresponding  receptor,  the  plasma 
membrane  gets  engulfed  inside  the  cells  and  a  coated  pit  is  formed.  The  pit  
then separates from the plasma membrane and forms an endocytic vesicle and 
endosomes-membrane-limited  transport  vesicles  with  a  polymeric  delivery  system  
inside.  The drugs are prevented from degradation by cellular detoxification enzymes 
as they are being  transported  inside  the  membrane-coated  endosome.  Therefore  its  
activity  is preserved.  The  endosomes  move  deep  inside  the  cell  and  fuse  with  
lysosomes. Lysosomal enzymes could break the bond between the targeting moiety (or 
targeted carrier). The drug would then be released from the drug delivery complex and 
might exit  a  lysosome  by  diffusion.  As  a  result  of  receptor-mediated  endocytosis  
and transport  inside  cells  in  membrane-limited  organelles,  targeted  polymeric  
drugs  no longer require a higher concentration gradient across the plasma membrane. 
The two main   limiting   factors   of   this   strategy   are   the   interaction   of   
receptors   with corresponding ligands and the drug release from drug delivery system 
and lysosomes.  
 
2.4.3 Advantages of Prodrugs 
Polymeric  conjugates  of  conventional  drugs  (polymeric prodrugs)  have  several  
advantages  over  their  low molecular  weight  precursors.  The  main  advantages 
include:  (1)  an  increase  in  water  solubility  of  low soluble or insoluble drugs, and 
therefore, enhancement of  drug  bioavailability;  (2)  protection  of  drug  from 
deactivation  and  preservation  of  its  activity  during circulation,  transport  to  
targeted  organ  or  tissue  and intracellular trafficking; (3) an improvement in 
pharmacokinetics; (4) a reduction in antigenic activity of the drug leading to a less 
pronounced immunological body response; (5) the ability to provide passive or active 
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targeting of the drug speciﬁcally to the site of its action; (6) the possibility to form an 
advanced complex drug delivery system, which, in addition to drug and polymer 
carrier, may include several other active components that enhance the speciﬁc activity 
of the main drug. (Khandare and Minko, 2006) 
2.4.4 Current progress in Prodrugs 
Table 2.1: Polymer-drug conjugates in clinical trials based on classic chemotherapeutic 
agents 
 
Currently, more than 14 polymer–drug conjugates have already  reached clinical trials 
and only one is based  on active targeting (N-[2-hydroxypropyl]methacrylamide 
[HPMA] copolymer–doxorubicin [Dox]–galactosamine conjugate, PK2). The  most 
advanced conjugate is Opaxio ®  (poly-l-glutamic acid [PGA]–paclitaxel conjugate, 
formerly known as Xyotax ®  from Cell Therapeutics Inc.), which is expected to reach 
the market  in the near future as a potential treatment for  ovarian,  non-small-cell  lung  
and  oesophageal  cancer. All these compounds are built on orthodox 
chemotherapeutic agents; for example, Dox (topoisomerase II inhibitor plus DNA 
intercalating agent plus reactive oxygen species  production), camptothecin and 
derivatives (topoisomerase I inhibitor),  paclitaxel (microtubule stabilizer)  and  









Formed by esteriﬁcation of vitamin E succinate with polyethylene glycol 1000, TPGS  
is  a  water-soluble  derivative  of  natural  vitamin  E. It  is  an  amphiphilic  
macromolecule  comprising  of a hydrophilic polar head and a lypophilic alkyl tail. 
With a hydrophobic–lipophilic balance (HLB) of 13, it has a molecular weight  of 
approximately 1542 Da. Physically, it is a waxy solid with colour varying from white 
to light brown and has a melting point of approximately 37-41°C. (Fischer et al., 2002) 
Due to its amphiphilic nature and large surface area, TPGS can be used as an 
absorption enhancer, emulsiﬁer and solubilizer, and has wide applications in the food 
industry . (Dong et al., 2008) It is also a safe and effective form of Vitamin E for 
reversing or preventing Vitamin E deﬁciency due to its good oral bioavailability. 
TPGS can enhance the solubility and bioavailability of poorly absorbed drugs by 
acting as a carrier in drug delivery systems, thus providing an effective way to improve 
the therapeutic efficiency   and   reduce   the   side   effects   of   the   anticancer drugs. 
(Youk et al., 2005) Due to its ability to inhibit the P-glycoproteins, it is able to act as a 
vehicle for drug delivery by allowing increase drug permeability across the cell 
membranes and enhanced absorption of the drugs. (Mu and Feng, 2003; Dintaman and 
Silverman, 1999) Increased emulsiﬁcation efficiency  and  enhanced  cellular  uptake  
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of  nanoparticles  by TPGS  could  result  in  increased  cytotoxicity  of  the  
formulated drug to the cancer cells. In recent studies, it is known  that  TPGS  also  
possess  potent  antitumor activity and  has  effective  apoptosis  inducing  properties. 
(Youk et al., 2005; Dintaman and Silverman, 1999) TPGS is thus an ideal candidate 
for polymeric conjugation of the drugs that have problems in pharmacokinetics, that is, 
in the process of ADME (Cao and Feng, 2008; Anbharasi et al., 2010) 
2.5.1 Bioavailability Enhancer 
The oral absorption of highly polar and macro-molecular drugs is frequently limited  
by  poor intestinal wall permeability. Some physicochemical properties  that  have  
been  associated  with  poor membrane  permeability  includes  low  octanol/aqueous 
partitioning, presence   of   strongly   charged functional groups, high molecular 
weight, a substantial  number  of  hydrogen-bonding  functional groups and high polar 
surface area. For  some  compounds,  permeation  through  the intestinal  epithelium  is  
hindered  by  their  active transport   from   the   enterocyte   back   into   the intestinal  
lumen.  The  secretory  transporters  involved   in this hindrance may include   P-
glycoprotein   (P-gp),   the family of multidrug resistance-associated proteins, and  
possibly  others. (Prasad et al., 2003)  
 
P-gp is a 170kDa membrane protein which functions as an ATP-dependent drug effux 
pump. It acts to lower the intracellular concentration of drugs. P-gp removes a large 
number of chemically unrelated drugs extending over many therapeutic indications 
such as anti-cancer drugs, steroids, antihistamines, antibiotics, calcium-channel 
blockers and anti-HIV peptidomimetics.  This in turn reduces the cytotoxic activity of 
anticancer drugs. Furthermore, an increased expression P-gp has been observed in 
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human tumours resulting in failure of chemotherapy due to drug resistance. (Dintaman 
and Silverman, 1999; Boudreaux et al., 1993)  
 
It  has  been  shown (Sokol et al., 1991) that  the  coadministration  of TPGS with 
Cyclosporin A (CyA) in patients with cholestatic liver disease allows a  40-72%  
reduction  of  CyA  dose  within  2  months.  A similar effect was recently observed in 
children after liver transplantation.(Boudreaux et al., 1993) Chang et al. evaluated the 
effect of TPGS on the oral pharmacokinetics of cyclosporin A in healthy volunteers, 
and suggested that enhanced absorption, decreased counter transport by P-gp is 
responsible for the observed decrease in apparent oral clearance.(Chang et al., 1996) It 
was also demonstrated that TPGS can enhance the cytotoxicity of doxorubicin, 
vinblastine, paclitaxel and colchicines in the G185 cells, by acting as reversing agent 
for P-gp-mediated  multidrug  resistance  (Dintaman and Silverman, 1999; Ismailos et 
al., 1994) 
 
2.5.2 Solubilization Enhancer 
As TPGS is a non-ionic water soluble derivative of Vitamin E, it has been found to 
enhance the bioavailability of cyclosporin and amprenavir by enhancing solubility 
and/or permeability, or reducing intestinal metabolism (Sokol et al., 1991). TPGS has 
the ability to form micelles above the critical miceller concentration (CMC) and 
improve solubility of lipophilic compounds. Previous reports suggested that 
coadministration of TPGS enhanced oral absorption of cyclosporin A due to improved 
solubilization by micelle formation (Sokol et al., 1991; Boudreaux et al., 1993).   
Much work has been done to investigate the effect of TPGS on the aqueous solubility 
of poorly water soluble  drugs.  It  was  shown  that  TPGS  can  enhance  the  
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solubility  and  bioavailability  of poorly absorbed drugs by acting as a carrier in drug 
delivery systems, thus providing an effective way  to  improve  the  therapeutic  
efficiency  and  reduce  the  side  effects  of  the  anticancer  drugs. This is extremely 
important as commercial preparations of hydrophobic drugs like doxorubicin, 
paclitaxel and docetaxel require the aid of adjuvants to improve their solubility. The 
elimination of adjuvants which might cause adverse side effects to the patients would 
increase the well-being of patients.  
2.5.3 Anti-cancer properties 
α-Tocopheryl succinate (TOS) is a succinyl derivative of vitamin E that differs from 
other vitamin E derivatives  in  that  TOS  itself  does  not  act  as  an 
antioxidant.(Neuzil, 2002) Recently, it has been reported that TOS has anticancer 
properties against a wide variety  of  human  cancer  cells, including  leukemias and  
melanomas,  as  well  as  breast,  colorectal,  lung and prostate cancers(Neuzil et al., 
2001; Zhang et al., 2002). In experimental animal models  with  human  cancer  
xenografts,  TOS  suppressed tumor growth, both alone and in combination with other 
anticancer agents (Barnett et al., 2002; Weber et al., 2002). Furthermore, the 
observation that the antiproliferative activity of TOS was less potent in normal cell 
types, including intestinal epithelial cells, prostate cells, and hepatocytes, than in tumor 
cells (Neuzil et al., 2001; Barnett et al., 2002). These findings suggest that TOS may 
be clinically useful as an anticancer agent. The anticancer activity of TOS is mediated 
by its unique apoptosis-inducing  properties,  which  appear to be mediated through 
diverse mechanisms involving the generation of reactive oxygen species (ROS)(Ottino 
and Duncan, 1997). ROS can damage DNA, proteins, and fatty acids  in  cells,  




As TPGS is a PEG 1000-conjugated derivative of TOS, it has been found to have 
antitumor efficacy comparable with that of TOS. (Youk et al., 2005) This gives an 
added advantage of chemotherapeutic properties when administered along with anti-




Figure 2.13:  Structure of Docetaxel 
Docetaxel is a second-generation taxane derived from the needles of the European yew 
tree Taxus baccata. Taxanes include paclitaxel and docetaxel, both of which are known 
to have antineoplastic activity against a wide variety of cancer cells. Both  compounds  
were approved by the U.S. Food and Drug Administration (FDA) for  the  treatment  of  
several  carcinomas  including  breast, advanced ovarian, non small cell lung, head and 
neck, colon, and AIDS-related Kaposi′s sarcoma.  
Docetaxel (807g/mol), trademarked as Taxotere by Rhone Poulenc Rorer, is a complex 
diterpenoid which features a rigid taxane ring and a ﬂexible side chain. Docetaxel 
differs from paclitaxel at two positions in its chemical structure. It has a hydroxyl 
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functional group on carbon 10, whereas paclitaxel has an acetate ester and a tert-butyl 
substitution exists on the phenylpropionate side chain. Docetaxel falls into the group of 
mitotic inhibitors which induces apoptosis by interfering with microtubule dynamics. 
DTX works particularly by preventing tubulin depolymerisation. Actively dividing 
cells are thus induced to undergo apoptosis. 
One of limitations of DTX is that it shows very low water solubility, and the only 
available formulation for clinical use consists of a solution (40 mg/mL) in a vehicle 
containing a high concentration of Tween 80.
16
 Unfortunately, this vehicle has been 
associated with several hypersensitivity reactions such as nephrotoxicity, 
neurotoxicity, and cardiotoxicity. In order to eliminate the Tween 80-based vehicle  
and  in  the  attempt  to  increase  the  drug  solubility, alternative dosage forms have 
been suggested, e.g., liposomal formulations for controlled and targeted delivery of the 
drug.  (Fernández-botello et al., 2008) 
2.7 Herceptin 
HER2  is  a  185-kDa  transmembrane  oncoprotein encoded by the HER2/neu gene 
and over-expressed in approximately 20 to 25% of invasive breast cancers. (Pohlmann 
et al., 2009) 
Herceptin® (Trastuzumab, HER), a humanized recombinant anti-HER2/neu MAb, can 
specifically bind to the membrane region of HER2/neu with a high affinity, inhibiting 
signal transduction and cell proliferation. Moreover, HER have been approved as a 
therapeutic agent of breast cancer by FDA, and it showed significant biostatic activity 
both as a single agent and the combination with traditional cytotoxic  chemotherapy in  





the  treatment  of  HER2/neu over-expressing metastatic breast cancer patients. (Tai et 
al., 2010) 
 
Figure 2.14: Signal Transduction by the HER Family and Potential Mechanisms of 
Action of Trastuzumab. (Hudis, 2007) 
 
The Signal Transduction by the HER family and potential mechanism of Action of 
Trastuzumab is shown in Figure 2.14. The four members of the HER family are HER1, 
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HER2, HER3, and HER4. There are receptor-specific ligands for HER1, HER3, and 
HER4 and an intracellular tyrosine kinase domain exists for HER1, HER2, and HER4. 
Phosphorylation of the tyrosine kinase domain by means of homodimerization or 
heterodimerization induces both cell proliferation and survival signalling. As HER2 is 
the preferred dimerization partner for the other HER family members, it is important 
for these two processes. 
 
The potential mechanisms of action of trastuzumab are shown in Panels B through F. 
Cleavage of the extracellular domain of HER2 leaves a membrane-bound 
phosphorylated p95, which can activate signal-transduction pathways (Panel B). 
Binding of trastuzumab to a juxtamembrane domain of HER2 reduces shedding of the 
extracellular domain, thereby reducing  p95 (Panel C). Trastuzumab may reduce HER2 
signalling by physically inhibiting either homodimerization, as shown, or 
heterodimerization (Panel D). Trastuzumab may recruit Fc-competent immune effector 
cells and the other components of antibody-dependent cell-mediated cytotoxicity, 
leading to tumour-cell death (Panel E). Additional mechanisms such as receptor down-








CHAPTER 3 SYNTHESIS AND CHARACTERIZATION 
OF TPGS-DTX CONJUGATE 
3.1  Introduction 
Polymer drug conjugation is one of the major strategies for drug modiﬁcations, which 
manipulates therapeutic agents at molecular level to increase their solubility, 
permeability and stability, and thus biological activity. As Docetaxel has low water 
solubility, its commercial preparation, Taxotere®, involves Tween 80 which is 
associated with hypersensitivity. Therefore, conjugation of TPGS-DTX has been 
designed to eliminate the use of Tween 80.  
Previous conjugates of Docetaxel have been designed with the same aim of increasing 
drug solubility and bioavailability. These conjugates include DTX-Albumin(Esmaeili 
et al., 2009) and Chitosan-DTX(Lee et al., 2009).  Albumin-conjugated formulation of  
DTX was found to be more  soluble with enhanced in vivo characteristics and higher 
activity against tumor cells compared to Taxotere® while Chitosan-DTX showed  
markedly enhanced water solubility (>200 times), which could eliminate the toxic 
formulation of using Tween 80.  
Due to its amphiphilic structure and large surface area, TPGS has proven to be an 
effective emulsifier and solubilizer. Previously, TPGS-Doxorubicin(Cao and Feng, 
2008) and TPGS-Doxorubicin-Folate(Anbharasi et al., 2010) have been successful 
synthesized and have showed great potential to be a prodrug of higher therapeutic 




In order to improve the solubility and bioavailability of Docetaxel, the polymer drug 
conjugate was prepared by attachment of TPGS to DTX through an ester linkage. This 
was done by a two-step synthesis which consists of activation of TPGS to obtain a 
carboxyl group and further reaction of the carboxyl group with the hydroxyl group 
attached to C2’ of DTX. TPGS was activated by reacting the terminal hydroxyl group 
of the TPGS with succinic anhydride through the ring opening polymerization 
mechanism in the presence of DMAP. (Cao and Feng, 2008) This resulted in the 
formation of TPGS-SA which was further reacted with Docetaxel in the presence of 
DCC and DMAP to form TPGS-DTX. The conjugate was characterized by Nuclear 
Magnetic  Resonance (ˡH NMR) and the molecular weight of the conjugate was found 
by using Gel Permeation Chromatography (GPC) which further confirmed the 
conjugation of the drug with TPGS. 
 
3.2  Materials 
TPGS was obtained from Eastman Chemical Company (UK). Docetaxel was obtained  
from Jinhe  Biotechnology  Company (China). N,N
’
-dicyclohexylcarbodiimide (DCC),  
4-dimethylaminopyridine (DMAP),  succinic  anhydride  (SA),  triethylamine  (TEA) 
and diethyl ether were obtained from Sigma–Aldrich (St. Louis, MO, USA). All 
solvents used are HPLC grade, which include  dichloromethane (DCM) and 
tetrahydrofuran (THF) from  Sigma-Aldrich. All  reagent  water  used  in  the 







3.3  Methods 
3.3.1 Synthesis of TPGS-DTX conjugate 
3.3.1.1 Activation of TPGS 
TPGS was activated by the ring-opening polymerization mechanism in the presence of 
DMAP. Following what Cao et al. has done previously, TPGS (0.77 g), succinic 
anhydride (0.10 g) and DMAP (0.12 g) were mixed and allowed to react at 100° C 
under nitrogen atmosphere for 24 hours.  The mixture was cooled to room temperature 
and taken up in 5.0 mL cold DCM. The resulting mixture was then filtered to remove 
excessive succinic anhydride and precipitated in 100 mL diethyl ether at -10°C 
































DMAP, 100 deg C
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3.3.1.2 TPGS-DTX Conjugation 
TPGS-DTX conjugate was synthesized using a method which employs the 
dicyclohexyl carbodiimide reaction in the presence of DMAP. (Liu et al., 2008) Instead 
of directly following what Liu et al has done previously, TPGS–COOH (0.386 g, 0.25 
mmol) was freeze-dried before use and directly mixed with DTX (0.2 g, 0.248 mmol), 
DCC (0.052 g, 0.25 mmol), DMAP (30.5 mg, 0.25 mmol) and dichloromethane (10.0 
mL, dried by calcium hydride) in a round bottom flask. The reaction was left to 
proceed at room temperature for 24 hours. The resulting precipitate of 
dicyclohexylurea was removed by filtration and the product was collected by 
precipitation in diethyl ether. The TPGS–DTX conjugate was purified by re-
precipitation in diethyl ether three times in order to remove the unreacted DTX. The 
white precipitate was then dried in vacuum to obtain TPGS-DTX conjugate. The 
synthetic scheme of the TPGS-DTX conjugate is shown below in Figure 3.2. 
 



























































3.3.2 Characterization of TPGS-DTX 
3.3.2.1  1H-NMR 
The molecular structure of TPGS-DTX and the percentage conjugation of DTX to 
TPGS was determined by ¹H-Nuclear  Magnetic  Resonance  (
1
H-NMR)  in  CDCl 3 
solvent on  a  Bruker  AMX-500  NMR  spectrometer  (Bruker Instruments, Billerica, 
MA, USA) at a frequency of 500 MHz.  
 
3.3.2.2 GPC 
The Mn and polydispersity index (PDI) of TPGS-DTX were determined by gel 
permeation chromatography (GPC) with measurements carried out at room 
temperature using a Waters  2414 refractive  index  (RI)  detector,  Waters  717  plus  
Autosampler  and  Jordi  Organic  GPC column (7.8 × 300 mm × 5 μm). THF with 1% 
triethylamine was used as the mobile phase and delivered at a flow rate of 1.0 ml/min 
at 40°C. Narrow polystyrene  standards  (Polysciences,  Inc.,  Warrington, PA) were 
used to generate a calibration curve. The  injection  volume  was  100µl  of  standard  
or  sample  solution  (0.1  %  w/v standard  or  sample  in  mobile  phase) and each run 
took 45mins. The  data  obtained  were  recorded  and manipulated using the 












Figure 3.3: ¹H NMR spectra of a)DTX and b)TPGS-DTX 
 
Previously, it has been demonstrated that the 2’- and 7-hydroxyl groups of paclitaxel, 








al., 1999) Reaction at the 2’-hydroxyl group is preferred because there is steric 
hindrance at the 7-hydroxyl group, reducing reactivity. (Greenwald et al., 2003) DTX 
has also been successfully conjugated with PEG at the 2’ carbon. (Liu et al., 2008) 
Therefore, TPGS-DTX conjugate was synthesized by reacting the 2’-hydroxyl group 
of DTX with succinoylated TPGS in the presence of DCC and DMAP. Excessive DTX 
was introduced to a complete reaction with TPGS-COOH. The unreacted DTX was 
then removed by re-precipitation in diethyl ether three times for the purification of the 
TPGS-DTX conjugate. The yield of the conjugate was found to be 0.36 g i.e. 51%. 
 
The conjugation was confirmed by 
1
H NMR with CDCl3 used as the solvent. The 
typical 
1
H NMR spectra of DTX and TPGS-DTX conjugate are shown respectively in 
Figure 3.3(a, DTX; b, TPGS-DTX). A distinct peak at 3.6ppm can be observed in the 
spectra of TPGS-DTX. This resonance peak at 3.6ppm is characteristic of methylene 
protons of poly ethylene oxide (PEO) in TPGS. The presence of this characteristic 
peak in the spectra of TPGS-DTX confirms the presence of TPGS, which indicates that 
conjugation between TPGS and DTX. More importantly, in the spectrum for TPGS-
DTX, the significant reduction of the resonance at δ=4.62ppm which is observed in the 
spectrum of DTX and corresponds to the proton of the 2’ carbon confirms that 
conjugation has taken place. The ratio of the integrated-area for the resonances at 
4.62ppm and 1.34ppm (9H, t-butyl group of DTX) for DTX was compared with the 
same ratio for TPGS-DTX to calculate percentage of DTX reacted. The reduction was 
found to be ~98%,  indicating the completion of the conjugation at the C2’ position of 
DTX. (Liu et al., 2008) DTX content in the conjugate was determined by comparing 
the ratio of the integrated area for the resonances at 1.3 ppm (t-butyl group of DTX) 
47 
 
and 3.6 ppm (TPGS). The DTX content in the conjugate was found to be 




Figure 3.4: Gel permeation chromatography (GPC) of the TPGS-COOH, DTX and 
TPGS-DTX conjugate. 
 
The conjugation between TPGS and DTX was further confirmed by gel permeation 
chromatography which is based on the ability of molecules to move through a column 
of gel that has pores of clearly-defined sizes. Retention time is influenced by the size 
of molecules. Smaller molecules are able to enter the pores easily and get eluted later 
while larger molecules are unable to enter the pores and pass through the columns 
quickly and thus get eluted earlier.  
 





From the GPC analysis, DTX-TPGS was eluted earlier than the DTX and TPGS, 
indicating that DTX was conjugated to TPGS. The number averaged molecular weight 
of the conjugate, DTX and the activated TPGS was found to be 2448, 668 and 2111 
respectively. The ratio of the weight-averaged over the number-averaged molecular 
weight of the conjugate (Mw/Mn) was 1.026. The slight increase might be due to the 
DTX conjugation and the loss of low molecular weight TPGS fraction in the 
purification process.  
 
3.5 Conclusions 
In conclusion, TPGS-DTX conjugate was successfully synthesized by reacting TPGS 
with DTX. Prior to the conjugation, TPGS was activated by the ring-opening 
polymerization mechanism to obtain a carboxyl group is needed for forming an ester 
linkage with hydroxyl group of DTX. The conjugate was characterized by 
1
H-NMR to 
study the molecular structure and confirm the conjugation. GPC results further 









CHAPTER 4 IN VITRO STUDIES OF TPGS-DTX 
CONJUGATE 
4.1   Introduction 
Upon successful synthesis of the conjugate, the efficacy of the prodrug has to be put 
into test. As the prodrug formulation aims to provide a better means of drug delivery to 
the cancer cells, it is important to know how the conjugate fares in the in vitro 
environment.  
 
In the TPGS-DTX conjugate, the DTX is kept in an inactive state by being conjugated 
with TPGS through an ester bond. In order for the drug to have a therapeutic effect on 
the cells, the  drug  release  from  the  conjugate  is  an  important  factor  to  be  
considered. From previous invitro drug release studies done on conjugates which 
makes use of the succinate linker, it can be seen that the parent drug is released via 
cleavage of the succinate linker under physiological conditions. For example, in 
Chitosan-DTX conjugate, drug release experiments were done upon incubation in rat 
plasma, simulated intestinal ﬂuid containing 1% pancreatin (SIF, pH 7.5), and 
simulated gastric ﬂuid containing 0.32% pepsin (SGF, pH 1.2) at 37 °C. Complete 
release of DTX was attained in SGF within 8 h, whereas the similar extent of DTX 
release was observed within 72 h at pH 7.5. (Lee et al., 2009) DTX-Albumin 
conjugates also gave similar response to pH. Rapid   ester   bond hydrolysis and 
degradation was reﬂected in  the  release  of  about  54%  of  DTX  from  the conjugate  
in  24  h at pH 5.5 compared to slower release at pH 7.4.(Esmaeili et al., 2009) 
Predicting that the drug  release  is  mediated  by  simple  hydrolysis,  release kinetics 





The  efficacy  of  the  prodrug  formulation is also  heavily dependent  on  the  ability  
of  the  formulation  to  bypass  the  resistances  exerted  from  the cancer cells. As 
mentioned earlier, the multidrug-resistant P-gp transporter expressed by most of the 
cancer cells (Thiebaut et al., 1987; Ling, 1997) poses as a huge barrier to 
chemotherapy. TPGS is said to enhance the cellular uptake in the human  intestinal  
Caco-2  cell  line (Traber et al., 1988) and  in  the  human  colon carcinoma cells (Win 
and Feng, 2006) by inhibiting the action of P-glycoprotein. Therefore, in vitro cell 
viability study was done using CCK-8 assay in MCF-7 breast cancer cells to study the 
effect of the conjugates in comparison to the commercial formulation, Taxotere®. 
 
 
4.2  Materials 
Hydrochloride, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl  tetrazolium  bromide  
(MTT),  disodium phosphate, citric acid, phosphate  buffered  saline  (PBS), 
Dulbecco’s  Modified  Eagel  Medium  (DMEM),  penicillin–streptomycin  solution, 
Trypsin–EDTA,  were obtained from Sigma–Aldrich (St. Louis, MO, USA). Fetal 
bovine serum (FBS) was received from Gibco (Life Technologies, AG, Switzerland). 
All solvents used are HPLC  grade,  which  include  dichloromethane  (DCM),  
dimethyl  sulfoxide  (DMSO) from  Aldrich,  ethyl  acetate  from  Merck.  All  reagent  
water  used  in  the laboratory  was  pre-treated  with  the  Milli-Q  Plus  System  






4.3  Methods 
4.3.1 In vitro Release Studies 
In vitro release of DTX was investigated by a dialysis method in prepared buffer 
solution (pH 3 or 5) or 10 mM PBS (pH 7.4) at 37
o
C, respectively. Buffer solutions of 
pH 3 and 5 were prepared according to the composition below: 
Table 4.1: Composition of buffer solution used in drug release studies 
Buffer solution 0.2M Na2HPO4/ml 0.1M Citric Acid/ml 
pH 3 20.55 79.45 
pH 5 51.50 48.50 
 
The conjugate solution of 200 mg/mL equivalent DTX concentration was placed in a 
standard grade Regenerated Cellulose Dialysis Membrane (Spectra/Por® 6, MW 
cutoff: 1000) and incubated in 20 mL of the prepared buffer/ PBS solution with gentle 
shaking in a water bath. Tween 80 was added to the buffer solution to avoid DTX from 
binding to the wall. The incubated solution was collected at designated time points and 
equal volume of fresh buffer was compensated. The amount of DTX released was 
measured using high performance liquid chromatography (HPLC, Agilent LC1100). 
4.3.2 Cell Culture 
MCF-7 breast adenocarcinoma cells (American Type Culture Collection, VA) were 
employed as in vitro models. The cells were cultured in 25cm
2
 culture flasks in the 
DMEM medium supplemented with 10% FBS, 1% penicillin–streptomycin solution, 
and incubated in SANYO CO2 incubator at 37
o
C in a humidified environment of 5.0% 
CO2. The medium was replenished every day until confluence was achieved. The cells 
were then washed with PBS and harvested with 0.125% Trypsin–EDTA solution. 
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4.3.3 In Vitro Cell Cytotoxicity 
MCF-7 cells were seeded in 96-well transparent plates at a density of 5 x10
3
 cells/well 
and incubated for 24 h to allow cell attachment. The medium was then replaced by the 
free DTX or TPGS–DTX conjugate at various drug concentrations from 0.002 to 100 
μg/ml in the medium. The cell viability was determined by the MTT assay. At the 
designated time intervals 24, 48, 72 h, the medium was removed and the wells were 
washed twice with PBS. Ten percent MTT (5 mg/mL in PBS) in medium was added 
and the cells were incubated for 3–4 h. After that, the precipitant was dissolved in 
DMSO and each well was finally analyzed by the microplate reader with absorbance 
detection at 570 nm. 
 
Cell viability refers to the extent to which cells are alive after exposing to certain 
amount of drug. The viability can be calculated using the equation below:  
 
Cell Viability = (Abss / Absc) ×100 , 
 
where Abss and Absc are the intensity of MTT fluorescent signals from cells incubated 
with drug suspension and drug-free medium (control), respectively. From cell viability 
versus drug concentration profile, the drug concentration at which 50% of the cells 








4.4  Results and Discussion 
4.4.1 In Vitro Drug Release 
The drug release profiles of TPGS-DTX conjugate in release medium of different pH 
were shown in Figure 4.1. 
 
Figure 4.1: Release of DTX from TPGS-DTX conjugate incubated in phosphate buffer 
at 37
o
C (mean ± SD and n = 3) 
 
From Figure 4.1, it can be observed that during the first 24 h of incubation, there was 
an initial burst release of DTX for all the 3 different pHs. However, the release is also 
pH dependent. The lower the pH value, the faster the drug release. The cumulative 
release at pH 3.0 reached 42.9 ± 0.5% after 24 h, compared to 38.6 ± 3.8% and 33.2 ± 


























pH 3.0 pH 5.0 pH 7.4
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Often, fast release was needed so as to exert the therapeutic effects of the drug within a 
short period. However, the initial burst must not exceed the therapeutic window of the 
drug which would otherwise cause adverse effects on the patients. DTX might be 
released from the TPGS-DTX conjugate by hydrolysis of the ester linkage which was 
dependent on the pH value. This explains the faster drug release at lower pH. This 
effect is desirable as drug release inside cancer cells could be sped up when the 
conjugate is exposed to the acidic pH of the lysosome. Also, in or near the tumour 
tissue the pH is slightly acidic as compared to the healthy tissue.(Thistlethwaite et al., 
1985) The release profile confirmed that the conjugate breaks up more easily, hence 
there is faster drug release under mild acidic conditions and it is relatively more stable 
at neutral pH (pH 7.4), which enables the transport of the prodrug to tumour cells in 
the blood stream. 
 
4.4.2 In Vitro Cell Cytotoxicity 
The MCF-7 breast cancer cell line was employed as the in vitro model to investigate 
the cytotoxicity of the TPGS-DTX conjugate in close comparison with the pristine 
DTX as a positive control. Figure 4.2 shows the viability of the MCF-7 cells after 24, 
48, 72h culture with the TPGS-DTX conjugate compared to that of the pristine DTX at 




Figure 4.2: Cellular viability of MCF-7 breast cancer cells after 24, 48, 72 h culture 
with the TPGS-DTX conjugate respectively in comparison with that of Taxotere® at 
various equivalent DTX concentrations (mean ± SD and n=6). 
 
 
From Figure 4.2, the expected decreasing trend of the viability of the MCF-7 cells as 
the concentration of DTX was increased from 0.002 to 100µg/ml can be observed. 
Table 4.1 shows a more detailed presentation of the cell viability. The values in the last 
column, TPGS-DTX/Taxotere®, indicate the ratio of cytotoxicity between TPGS-DTX 
and Taxotere. Values more than 1 indicates higher cytotoxicity while values lower 
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Table 4.2: Comparison of cellular viability of MCF-7 breast cancer cells after 24, 48, 
72h culture with the TPGS-DTX conjugate and Taxotere® at various concentrations 











0.002  24 2.13 20.4 0.104 
 48 38.6 32.2 1.20 
 72 66.4 54.2 1.23 
0.02  24 23.6 28.2 0.838 
 48 50.4 48.0 1.05 
 72 70.8 65.5 1.08 
0.2  24 29.9 41.0 0.731 
 48 75.4 60.0 1.26 
 72 83.7 81.6 1.03 
10  24 56.5 66.2 0.854 
 48 82.3 93.8 0.878 
 72 89.6 96.9 0.925 
100  24 83.3 84.6 0.985 
 48 97.4 97.0 1.00 
 72 97.5 97.5 1.00 
 
It can be seen from Table 4.2 that during the first 24 hours, the commercial Taxotere® 
had a slightly more cytotoxic effect on the cell line compared to the TPGS-DTX 
conjugate at all different DTX concentrations (p<0.1). However, on subsequent days, 
the TPGS-DTX conjugate exhibited relatively higher cytotoxicity at low drug 
concentration and comparable cytotoxicity at high drug concentration as compared to 
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Taxotere® (p<0.1). For instance, at the DTX concentration of 0.002 μg/ml, MCF-7 
incubated with the prodrug showed a mortality of 2.13% on the first day while 
subsequently reaching a mortality of 38.6% and 66.4% on Day 2 and Day 3 
respectively. At the same time, MCF-7 incubated with Taxotere® at the same drug 
concentration showed a mortality of 20.4% on the first day, and only 33.2% and 54.2% 
on Day 2 and Day 3 respectively. This is likely to be a consequence in the difference in 
cellular pharmacokinetics such as slower endocytic capture of the prodrug compared to 
rapid diffusion of the parent drug. The accumulation and metabolism of the prodrug in 
the cells, together with increased drug released as seen in the in vitro DTX release 
profile over time are the likely reasons for this phenomenon. As described in Section 
4.4.1, the in vitro drug release of the TPGS-DTX conjugate on Day 1, Day 2 and Day 
3 were 33.2%, 36.6% and 39.0% respectively. In other words, less than half of the total 
amount of DTX contained in the prodrug was released to kill the cancer cells. This 
could mean that the prodrug has the ability to kill more cancer cells compared to 
Taxotere® in subsequent days if more DTX is released since the prodrug has a 
prolonged release of DTX over a period of time while Taxotere® supplies a high 
amount of DTX within a short period of time. 
 
The ability of the prodrug to cause higher mortality of the cells compared to 
Taxotere® with only less than half of the total amount of DTX contained in the 
prodrug was released is likely to be attributed to TPGS which has the ability to inhibit 
the MDR effect caused by p-glycoproteins. Table 4.3 shows the IC50 value, i.e. the 






Table 4.3: IC50 values (in equivalent μg/ml of DTX) of MCF-7 cells cultured with the 






 TPGS-DTX Taxotere® 











As described earlier, time is needed for endocytosis of the prodrug and the release of 
DTX from the prodrug, thus resulting in the higher IC50 value for the prodrug on the 
compared to that of Taxotere® on the first day. However, on subsequent days, the 
conjugate achieved lower IC50 values and the trend became more significant as the 
incubation time increases. This shows that with the prodrug formulation, lesser amount 
of DTX is required to give the same cytotoxic effects. This phenomena is extremely 
important as drug dosage can be reduced if administered as the prodrug compared to 
the commercial preparation. 
  
4.5 Conclusions 
Both in vitro drug release studies and in vitro cell cytotoxicity studies were performed 
in this chapter.  From the drug release studies, it can be seen that the release of DTX 
from TPGS-DTX is pH dependant. This can be attributed to the hydrolysis of the ester 
bond that links TPGS to DTX in the conjugate. This phenomena is of importance in 
chemotherapy as cancer cells tend to be slightly more acidic than normal cells.  
Desirable results were also achieved from the cell cytotoxicity studies. Other than the 
first 24h, lower IC50 values were obtained for TPGS-DTX compared to Taxotere®, 




From the in vitro results obtained, TPGS-DTX conjugate could serve as a more 
effective device to not only sustain the release of drug, but also to avoid intolerable 
adverse effect of DTX by allowing a lower dosage of DTX used while at the same time 

















CHAPTER 5 IN VIVO PHARMACOKINETICS OF TPGS-
DTX CONJUGATES 
5.1  Introduction 
Due to the much more sophisticated mechanisms that take place within the body, the 
activity of a formulation tested against in vitro models is sometimes unable to be used 
to predict  its efficacy  in  in  vivo  model (Johnson et al., 2001). Therefore, research 
involving animals has been essential to evaluate the formulation for efficacy and safety 
before proceeding to clinical trials.  
 
In this chapter, in vivo pharmacokinetics of TPGS-DTX and Taxotere® was 
investigated  on male SD rats to study the long circulation effect and drug retention 
effect of the prodrug. Liquid-liquid extraction was done on the blood collected  from  
the  rats  after  administration  and  is  the drug amount in the plasma was detected 
using HPLC with fluorescence detection. As the conjugate and drug was administered 
intravenously, a non-compartmental model  analysis  was done to obtain the values of 
various pharmacokinetic parameters.  
 
Previous research has shown that conjugation with TPGS improves the half life of the 
drug and the mean residence time of the drug in the plasma. This is probably due to the 
ability of TPGS to inhibit the P-glycoprotein mediated MDR. Prodrug conjugation of 
TPGS to Doxorubicin resulted in 3.81 times longer half-life of Doxorubicin compared 
to that of free Doxorubicin. The area-under-the-curve (AUC) of the conjugate, which 
is a key therapeutic index of a drug, was also increased by 23.6 times, indicating the 





Male Sprague-Dawley (SD) rats of 150-200 gm (or 4-5 weeks old) were supplied by 
the Laboratory  Animals  Centre  of  Singapore.  They  were  maintained  at  the  
Vivarium at The Centre for Life Sciences (CeLs)  in National University of Singapore. 
The animal caring, handling, husbandry and the protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC), CeLs , National University of 
Singapore. The animals were acclimatized at a temperature of 25 ± 2 ºC and a relative 
humidity of 50 – 60 % under natural light/dark conditions for 4 – 5 days before 
experiments.   
 
Saline  0.9%  w/v  sodium  chloride  (NaCl)  solution  was  obtained  from  B.Braun  
(B.Braun Corporation,  Germany).  Rats  anaesthesia  (Ketamine  24  mg/ml;  
Medetomidine  0.16mg/ml)  was  prescribed  by  Animal  Holding  Unit.  All  solvents  
including  acetonitrile, methanol  and  ethyl  acetate  were  of  HPLC  grade.  They  
were  used  without  further purification. 
 
5.3 Methods 
5.3.1 Injection of drugs 
The  rats  were  randomly  assigned  to  two  groups,  each  consisting of  six  rats.  
One  group  was given an intravenous administration of Taxotere® while another 
group was given an intravenous administration of the TPGS-DTX conjugate. 
Taxotere® and TPGS-DTX were diluted in normal saline containing 1.9% w/v NaCl to 
obtain the required injection volume of 1-1.5 ml. Intravenous injection was given via 
the tail vein at a 5mg/kg equivalent drug dosage. All the  rats  were  observed  for  
mortality,  general  condition  and  potential  clinical  signs.   
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5.3.2 Blood Collection, Sample Processing and Analysis 
The blood samples were collected by heparinised tube at 1, 4, 11, 24, 29, 34, 48, 96, 
168 hours post-treatment. Plasma samples were harvested by centrifugation at  
10000rpm for 10 minutes and stored at -20
o
C until analysis. Docetaxel in the plasma 
samples was extracted into 1ml of ethyl acetate and was left to evaporate in separate 
tubes. 100 µl of HPLC mobile phase A (acetonitrile/methanol/water = 45/5/50 ν/ν/ν) 
was added to the dried tubes and centrifuged at 10500 rpm for 15 minutes. 80 µl of the 
supernatant was transferred to HPLC vial inserts and 50 µl was injected into the 
column. An elution gradient was applied by increasing the proportion of A from 0 to 
100% in 50 minutes and then     the     system     was     brought     to     initial     
condition     of     100%     B (acetonitrile/methanol/water = 40/5/50 ν/ν/ν) and 
equilibrated for 4 minutes by holding at 100%  B.  The  flow  rate  was  1  ml/min  and  
the  total  run  time  was  55  minutes.  The Docetaxel concentration in plasma was 
determined using the standard curve obtained for known concentrations of Docetaxel 
in plasma processed similarly. The curve was found to be linear in the concentration 
range 10 ng/ml-10000 ng/ml with a slope of 46.8 ng/ml/h and R
2
  = 0.997. 
 
5.4 Results and Discussion 
The  plasma  concentration  level  of  DTX  was  determined  after  a  single 
intravenous injection  of  the  Taxotere®   or  TPGS-DTX  conjugate  at  a  dose  of  
5mg/kg  DTX equivalent in male SpD rats over a period up to 168 h.  
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Figure 5.1: Pharmacokinetic profile of the Taxotere® and the TPGS-DTX conjugate 
after i.v. injection in rats at a single equivalent dose of 5 mg/kg (mean ± SD and n = 6) 
 
The pharmacokinetic profiles of the drug concentration in the plasma for both 
Taxotere® and  the  TPGS-DTX  conjugate  were shown in figure 5.1. It can be seen 
from the profiles that the TPGS-DTX conjugate  exhibited  significant   improvement  
over  the commercial  formulation,  Taxotere®. The  drug  concentration in the plasma 
for rats administered with TPGS-DTX decreased slowly, indicating prolonged 
circulation while  the drug concentration in the plasma for rats administered with  
Taxotere® declined dramatically within 24 hours of drug administration. 
 
It  has  been reported from in vitro studies that  the  concentration  of  docetaxel  
required  to  reduce  murine  and  human  tumour  cell  survival  by  50%  (in  vitro 




















Taxotere®   
Toxic Level  (5340ng/ml)
Minimum Effective Level (35ng/ml)
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ensures that TPGS-DTX can assume a therapeutic effect (above 35 ng/ml) up to 168 h 
after the i.v. injection. It as implies that a single dose of TPGS-DTX can make an 
effective chemotherapy possible by potentially maintaining the drug level above the 
minimum therapeutic level over a much longer period of time than the free drug at an 
equivalent dose.  
 
The  pharmacokinetic  curves  in  Figure 5.1  were  analyzed by Kinetica software and 
the mean non-compartmental pharmacokinetic  parameters  were  obtained  (Table 5.1) 
The area under the curve (AUC) of the drug at a given dose, which represents the 
graphical area located under the curve of the drug concentration in plasma versus time, 
is a quantitative measurement of the in vivo therapeutic effect of a drug formulation. 
From the analysis of the pharmacokinetic results, the total AUC was found to be 
261000±25100ng●h/ml for TPGS-DTX, 8.6-fold larger than that of Taxotere® 
(30500±4850ng●h/ml), indicating that the prodrug formulation has higher therapeutic 
effect than Taxotere® in general at a dose of 5mg/kg.  
Table 5.1: Mean Non-compartmental Pharmacokinetic Parameters of SpD rats after 
Intravenous Administration of TPGS-DTX and Taxotere® Dose of 5 mg/kg 
 
Parameter  TPGS-DTX Taxotere® 
Tmax(h) 4 1 
Cmax(ng/ml) 5890±857 10800±522 
AUC0-∞ (ng●h/ml)  261000±25100 30500±4850 
t½ (h)  124±14.2 5.24±1.96 
MRT(h)  162±22.8 2.98±1.07 
CL(ml/h/kg) 12.3±3.6 161±20.6 
AUC is area under concentration-time curve  
t1/2  is the biological half-life   
MRT stands for mean residence time  
CL stands for plasma clearance 
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The peak value of the drug concentration in the plasma, Cmax was only 
5890±857ngh/ml for the TPGS-DTX while the Cmax was 10800±522ngh/ml for 
Taxotere®. The  maximum  tolerated  dose  (MTD)  for  Taxotere® has  been reported 
to be 1.6-fold lower than that of Taxol®, which was estimated to be 5,340 ng/ml (Riou 
et al., 1992; Hill et al., 1994; Bissery, 1995) Although both TPGS-DTX and 
Taxotere®  exceeded the maximum tolerated level at some point of time during the 
first 10 hours, the Cmax of TPGS-DTX is only half of the Cmax of Taxotere®. This 
indicates that the prodrug formulation have potential to result in reduced side effects 
compared to Taxotere®.  
 
Furthermore, the longer t max  of  TPGS-DTX  (4h)  compared  to  Taxotere®  (1h)  
implied  that  the  conjugation of TPGS to the drug can prevent the exposure of the 
drug all at one time in the body. The half-life (t1/2 ), which is the time at which the drug 
concentration reduces to 50% of its initial value, of the TPGS-DTX was found to be  
124±14.2h, which is 23-fold longer than that for Taxotere® (5.24±1.96h), The longer 
circulation time was attributed to the much lower plasma clearance for TPGS-DTX 
(12.3 ml/h/kg) compared  to Taxotere® (161ml/h/kg), due to the bio-enhancing ability 




In this chapter, in vivo pharmacokinetic studies were performed on SpD rats to 
evaluate the in vivo efficacy of TPGS-DTX in vivo compared to Taxotere®. TPGS-
DTX showed a long circulation effect of 168hours while maintaining drug 
concentration levels in the therapeutic window of DTX compared to 24hours of 
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circulation for Taxotere®. This resulted in TPGS-DTX having a 8.6-fold higher AUC, 
24-fold longer half-life, further confirming the effect of TPGS on prolonged 
circulation. In addition, TPGS-DTX reached the Cmax value at 4 hours, later compared 
to 1hour for Taxotere®. As the Cmax value achieved by TPGS-DTX is still higher than 
the maximum tolerated level of the drug, future work can be done to optimise the 






















CHAPTER 6 SYNTHESIS AND CHARACTERIZATION 
OF TPGS-HER-DTX CONJUGATE 
6.1 Introduction 
From the earlier chapters, it can be observed that conjugation of TPGS to DTX 
brought about improved efficacy of DTX both in vitro and in vivo. By conjugating 
with TPGS, the problem of solubility can be solved, removing the need to use 
Tween80 as the adjuvant.  
 
This chapter aims to introduce Herceptin to the conjugation of TPGS and DTX. This 
would allow the resulting conjugate to target actively instead of just passive targeting 
with TPGS can provide. The aim of targeted drug delivery is to decrease the  
nonspeciﬁcity  of  prodrug  to  the  healthy  cells  and increase its speciﬁcity to the 
cancer cells by attaching a targeting moiety to the inactive prodrug such that the active 
drug  may  then  be  released  in  the  cancer  cells  without affecting the healthy 
cells.(Groot et al., 2001)   
 
Herceptin is a  humanized  recombinant  anti-HER2/neu  MAb,  which can specifically 
bind to the membrane region of HER2/neu with a high affinity, inhibiting signal 
transduction and cell proliferation. Moreover, Herceptin has been approved as a 
therapeutic agent of breast cancer by FDA, and synergistic antitumor effects have been 
found when Herceptin is combined with chemotherapeutic agents such as Docetaxel. 
(Sun and Feng, 2009) Research involving Herceptin in conjugation includes HER–
PEG–ADV conjugates which have been synthesised for retargeting gene therapy to 
breast cancer cells. These conjugate vectors were found to be feasible to overcome the 
limitation factor  associated  with  immune  response  and  targeting  for adenoviral 
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gene delivery. Results shown that HER–PEG–ADV were capable of enhancing 
transduction efficiency onto the breast cancer cells via HER2/neu as a targeting moiety 
and also enveloping of PEG on the surface of ADV reducing the extent of immune 
response. (Jung et al., 2007) Other than Herceptin, Folic acid has also been used as a 
targeting moiety in prodrug conjugation research. Conjugation of Doxorubicin to 
TPGS and Folic acid have shown higher cellular uptake and higher cytotoxicity of 
MCF-7 cells compared to TPGS-DOX and pristine DOX formulations. (Anbharasi et 
al., 2010) 
 
For the TPGS-DTX-HER conjugate in this research, the chemical structure of DTXSX 
and TPGS-COOH was characterised by 
1
H NMR (CDCL3). DTX-NHS, TPGS-NHS 
and TPGS-HER-DTX conjugation were characterized by MALDI-TOF and GPC. 
 
6.2 Materials 
TPGS was obtained from Eastman Chemical Company (UK). Docetaxel was obtained  
from Jinhe  Biotechnology  Company (China). Herceptin was from Roche 
(Switzerland) and purchased through the National Cancer Center (Singapore). N,N
’
-
dicyclohexylcarbodiimide (DCC),  4-dimethylaminopyridine (DMAP), 1-ethoxy-
carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), succinic  anhydride  (SA),  N-
hydroxysuccinimide (NHS), sinapic acid, trifluoroacetic acid, N,N-dimethylformamide 
(DMF), pyridine, acetone,  diethyl ether,  phosphate  buffered  saline  (PBS) and 
Dulbecco’s  phosphate  buffered  saline    (DPBS) were obtained from Sigma–Aldrich 
(St. Louis, MO, USA). All solvents used are HPLC grade, which include  
dichloromethane (DCM) and acetonitrile (ACN) from  Sigma-Aldrich. All  reagent  
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water  used  in  the laboratory  was  pre-treated  with  the  Milli-Q  Plus  System  



























6.3.1 Synthesis of TPGS-HER-DTX conjugate 
6.3.1.1 Succinoylation of TPGS 
Succinoylated TPGS was synthesized by the ring-opening polymerization mechanism 
in the presence of DMAP. TPGS (0.77 g), succinic anhydride (0.10 g) and DMAP 
(0.12 g) were mixed and allowed to react at 100° C under nitrogen atmosphere for 24 
hrs. The mixture was cooled to room temperature and taken up in 5.0 mL cold DCM. 
The resulting mixture was then filtered to remove excessive succinic anhydride and 
precipitated in 100 mL diethyl ether at -10°C overnight. The white precipitate was 
filtered and dried in vacuum to obtain succinoylated TPGS. 
 
 



























DMAP, 100 deg C
71 
 
6.3.1.2 Activation of  DTX 
Docetaxel was derivatized by succinic anhydride in pyridine, to 2’-succinyl-docetaxel 
(DTXSX).  After 3h at room temperature, a solution of 0.50 g (0.59 mmol) of 
docetaxel and 0.90 g (7.6 mmol) of succinic anhydride in 12 mL of pyridine was 
evaporated to dryness in vacuum. The residue was treated with 20 mL of water, stirred 
for 20 min, and filtered.  The precipitate was dissolved in acetone, water was slowly 
added, and the fine crystals were collected.   
Scheme 1:  
 DTX-2’-OH + Succinic Anhydride                             DTX-2’-O2CCH2CH2CO2H 
 
 
Docetaxel:     R = H 
DTXSX:                           R = COCH2CH2COOH 





6.3.1.3 Conjugation of TPGS-HER-DTX 
The carboxyl function of the DTXSX and TPGS-COOH was activated by the addition 
of NHS and EEDQ in dry DMF at 0 °C for 1 h respectively. The DMF solutions of the 
activated esters, DTX-NHS and TPGS-NHS were then added to a precooled (0 °C) 
solution of Herceptin in PBS (25 mM, pH 8.1). The solution was stirred at this 








Figure 6.3: Synthetic scheme of TPGS-HER-DTX 
 
6.3.2 Characterization of TPGS-DTX 
6.3.2.1 1H-NMR 
The molecular structure of activated DTX was determined by ¹H-Nuclear  Magnetic  
Resonance  (
1
H-NMR)  in  CDCl 3 solvent on  a  Bruker  AMX-500  NMR  
spectrometer  (Bruker Instruments, Billerica, MA, USA) at a frequency of 500 MHz.  
 
6.3.2.2 MALDI-TOF MS 
Matrix-Assisted Laser Ionisation/Deionisation Time of Flight(MALDI-TOF) Mass 
Spectrometry was employed for analysing the molecular weight of the TPGS-HER-
DTX conjugate. A Bruker Daltonics AutoReflex II TOF mass spectrometer, equipped 
NHS/EEDQ 
    DMF NH2 




with a nitrogen laser (337 nm) was used to obtain spectra with an ion extraction 
voltage of 30 kV  and laser irradiance for 100 shots in the linear mode and a transient 
recorder time resolution of 10 ns. The detector response from low-mass matrix ions 
was minimized by the application of a 5 µs deflection pulse.  
 
In this technique, analyte  molecules are embedded in a large molar excess of  a matrix 
substance, isolating the analyte molecules from one another thereby reducing  their 
intermolecular forces.  Energy from a laser beam is absorbed by the matrix, resulting 
in the disintegration of  the condensed phase. Photochemical processes with the matrix 
are thought to enhance or even induce analyte ionization. (Siegel et al., 1991) Matrix-
assisted  laser desorption ionization mass spectrometry (MALDI) has been effectively 
utilized  in  the molecular weight determination of various proteins with a claimed  
limit of 500 000 Da. The practical  limit for routine analysis of proteins is 
approximately 300 000 Da  with  a  sensitivity  in  the  low pmol  range  and  an 
accuracy of up to 0.1%. MALDI-TOF MS generates molecular ions of predominantly 
low charge state which are generally detected. It is also particularly well suited to the 
analysis of large biomolecules, as it is relatively insensitive to the presence of 
buffering agents, salts, and denaturants, which are often essential to maintain sample 
stability. (Siegel et al., 1991) 
 
 
Sinapinic acid dissolved in a 1:1 (v/v) mixture of acetonitrile:0.1% TFA, was used as 
the matrix.  (Safavy et al., 1999) 20 mg of Sinapic acid was dissolved in 1 ml of 
solvent and vortexed for 1 minute at 10000rpm. The supernatant was then used for 
sample preparation. Aliquots of the samples (0.5µL) were mixed with equal volumes 
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of  the sinapic acid matrix and deposited on a polished stainless steel sample stage and 
air-dried for analysis.   
 
The samples analyzed include Herceptin (for control), DTX-HER conjugate and 
TPGS-HER-DTX conjugate. The molecular weight increase of the TPGS-HER-DTX 
was  calculated  using  the  unconjugated  control (HER).  To make sure that the final 
conjugate consist of TPGS, HER and DTX, DTX-HER conjugate was analyzed to 
show that the increase in molecular weight from DTX-HER to TPGS-HER-DTX was 
due to TPGS and not another DTX.  
 
6.3.2.3 GPC 
The conjugation of  TPGS-HER-DTX  conjugate was confirmed by gel permeation 
chromatography (GPC) with measurements carried out at room temperature using a 
Waters  2414 refractive  index  (RI)  detector,  Waters  717  plus  Autosampler  and  
Jordi  Organic  GPC column (7.8 × 300 mm × 5 μm). The chromatographic procedures 
were performed at 23
oC. Water  was  used  as  the mobile phase at a ﬂow rate of 1.00 
mL/min. The  injection  volume  was  100µl  of  standard  or  sample  solution  (0.1  %  
w/v standard  or  sample  in  mobile  phase) and each run took 30 mins. The  data  
obtained  were  recorded  and manipulated using the Windows-based Millenium 2.0 













H NMR Spectra of Docetaxel 
Figure 6.5: 
1
H NMR Spectra of DTXSX 
From the NMR spectra of DTX and DTXSX, it can be observed that the spectra of 
DTXSX showed an additional signal at 2.5-2.7ppm as multiple peaks that could be 
related to OCOCH2CH2COOH moiety. This confirms the chemical shift for 
OCOCH2CH2COOH group in the spectrum of DTXSX. This result corresponds to that 
reported for similar synthesis procedures in literature. (Esmaeili et al., 2009) 
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6.4.2 MALDI-TOF MS 
    
    
     
 
Figure 6.6: MALDI-TOF MS of Herceptin (A), DTX-HER conjugate (B) and TPGS-
HER-DTX conjugate (C).  
From the MALDI-TOF MS of Herceptin, DTX-HER and TPGS-HER-DTX, it can be 
observed that there is an increase in MW which confirms the addition of DTX and 
TPGS. DTX-HER was analyzed to make sure that the the increase in MW for TPGS-
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Figure 6.7: Gel permeation chromatography (GPC) of the Herceptin and TPGS-HER-
DTX conjugate 
 
From the GPC results, it can be seen that the TPGS-HER-DTX conjugate was eluted 
earlier, further confirming that the conjugation had been successful. 
 
6.5 Conclusions 
The TPGS-HER-DTX conjugate was successfully synthesised by conjugated TPGS 
and DTX simultaneously to Herceptin. Both TPGS and DTX were first activated to 
obtain the carboxyl groups for reaction with the amine groups on Herceptin The 
activated TPGS and DTX were conjugated to Herceptin through amide bonds with the 
help of NHS and EEDQ. The conjugation was confirmed using MALDI-TOF analysis 
and it was found that the TPGS:HER:DTX is 1:1:1 by comparing the molecular 





weights achieved from the spectra. The conjugation was further confirmed by GPC in 
which the TPGS-HER-DTX conjugate was eluted earlier than Herceptin. 
 
Although desirable results were achieved from the characterization studies, more in-
depth molecular studies have to be done to find out the exact location at which TPGS 

















CHAPTER 7 CONCLUSIONS AND FUTURE WORK 
 
 
The main objective of this thesis is to develop and carry out characterization, in vitro 
and in vivo studies of polymer drug conjugate for new concept chemotherapy using 
TPGS as the polymer and DTX as the drug. In the later part, initial stages of TPGS-
HER-DTX were introduced. 
 
In Chapter 1, thesis objective were introduced along with a general background of the  
project and the concepts of prodrug conjugation. Chapter 2 highlighted some facts 
about cancer and the problems faced with chemotherapy.  
 
Chapter 3 introduces the TPGS-DTX conjugation which is the main objective of this 
thesis. TPGS-DTX was successfully conjugated with supporting characterization 
studies using 
1
H-NMR and GPC. In vitro studies of TPGS-DTX, including in vitro 
drug release and in vitro cytotoxicity studies, are discussed in Chapter 4. From the 
drug release studies, it can be seen that the release of DTX from TPGS-DTX is pH 
dependant which is of importance in chemotherapy as cancer cells tend to be slightly 
more acidic than normal cells.  Desirable results were also achieved from the cell 
cytotoxicity studies with lower IC50 values obtained for TPGS-DTX compared to 
Taxotere®, indicating a higher therapeutic efficacy of the prodrug formulation over the 
free drug. TPGS-DTX conjugate could serve as a more effective device to not only 
sustain the release of drug, but also to avoid intolerable adverse effect of DTX by 
allowing a lower dosage of DTX used while at the same time getting the same, if not 




In vivo studies of the conjugate were discussed in Chapter 5. With pharmacokinetics 
studies performed on SpD rats, TPGS-DTX showed a long circulation effect of 
168hours while maintaining drug concentration levels in the therapeutic window of 
DTX compared to 24hours of circulation for Taxotere®. This resulted in TPGS-DTX 
having a 8.6-fold higher AUC, 24-fold longer half-life, further confirming the effect of 
TPGS on prolonged circulation. Based on the above results, TPGS-DTX has great 
potential as a drug delivery system for DTX as it allows enhanced solubility, reduced 
MDR, and increase therapeutic efficacy and the same time eliminates the use of 
Tween80 as the adjuvant which is toxic to the body.   
 
In order to better enhance the concept of TPGS-DTX conjugation, Chapter 6 
introduces the synthesis and characterization of the TPGS-HER-DTX conjugate, which 
is still in the initial stages. From MALDI-TOF and GPC studies, TPGS-HER-DTX has 
been successfully conjugated and has great potential for further in vitro and in vivo 
studies. 
 
As for future work, more in vivo studies could be carried out for TPGS-DTX 
conjugate. Biodistribution studies could be conducted and tumour models could be 
adopted to explore the pharmacokinetic effects on existing tumours. More 
characterization studies could be done on TPGS-HER-DTX to further confirm the 
exact site of conjugation. In vitro studies such as in vitro release studies can be 
conducted and in vitro cytotoxicity and uptake studies can be conducted on SKBR-3 
cells to quantify the effects of herceptin as a targeting moiety. In vivo studies of TPGS-
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